1-3 of 3
Kelsey Tague
Close
Sort by
Journal Articles

B-PRISM (Precision Intervention Smoldering Myeloma): A Phase II Trial of Combination of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Omar Nadeem, Robert A. Redd, Julia Prescott, Amada Metivier, Kelsey Tague, Veronica Romines, Meredith Bertoni, Alexandra Savell, Rebekah Medina, Alexandra Distaso, Houry Leblebjian, Clifton C. Mo, Jacob P. Laubach, Adam S. Sperling, Paul G. Richardson, Irene M. Ghobrial
Journal: Blood
Blood (2021) 138 (Supplement 1): 4782.
https://doi.org/10.1182/blood-2021-148023
Published: 2021
Journal Articles

A Phase II Trial of the Combination of Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Omar Nadeem, Robert A. Redd, Julia Prescott, Kelsey Tague, Veronica Romines, Amada Metivier, Alexandra Savell, Houry Leblebjian, Alexandra Distaso, Clifton C Mo, Jacob P. Laubach, Adam S. Sperling, Paul G. Richardson, Irene M. Ghobrial
Journal: Blood
Blood (2021) 138 (Supplement 1): 2749.
https://doi.org/10.1182/blood-2021-149787
Published: 2021
Journal Articles

A Phase II Study of Daratumumab in Patients with High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma

Omar Nadeem, Robert A. Redd, Michael Z. Koontz, Jeffrey V. Matous, Andrew J. Yee, Jeffrey A. Zonder, Andrew Kin, Jacalyn Rosenblatt, Julia Prescott, Kelsey Tague, Veronica Romines, Meredith Bertoni, Amada Metivier, Rebekah Medina, Alexandra Savell, Houry Leblebjian, Alexandra Distaso, Clifton C Mo, Jacob P. Laubach, Adam S. Sperling, Paul G. Richardson, Irene M. Ghobrial
Journal: Blood
Blood (2021) 138 (Supplement 1): 1649.
https://doi.org/10.1182/blood-2021-149797
Published: 2021